A bill to amend the Federal Food, Drug, and Cosmetic Act to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved new drug application, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Senator for Georgia. Republican.
Last Updated: Dec 11, 2019
Length: 97 pages
What legislators are saying
“Casey and Isakson’s Landmark Over-the-Counter Drug Reform Passes Senate”
— Sen. Robert “Bob” Casey [D-PA] (Co-sponsor) on Dec 11, 2019
S. 2740 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2020). S. 2740 — 116th Congress: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. Retrieved from https://www.govtrack.us/congress/bills/116/s2740
“S. 2740 — 116th Congress: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.” www.GovTrack.us. 2019. January 18, 2020 <https://www.govtrack.us/congress/bills/116/s2740>
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019, S. 2740, 116th Cong..
|title=S. 2740 (116th)
|accessdate=January 18, 2020
|author=116th Congress (2019)
|date=October 30, 2019
|quote=Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.